OneMedNet Reports Strong Momentum and Industry Excitement at RSNA

Rhea-AI Summary

OneMedNet (Nasdaq: ONMD) reported strong engagement and growing commercial traction at the Radiological Society of North America (RSNA) Annual Meeting on Dec 10, 2025. The company said hospitals, imaging centers, and life sciences firms showed interest in joining its provider network and using the updated iRWD™ platform powered by Palantir Foundry. Attendees cited rapid deployment, regulatory-grade data quality, multimodal longitudinal coverage, and AI-enabled cohort discovery that shortens feasibility from weeks to minutes.

OneMedNet emphasized continued network growth, expanded multimodal assets, and a focus on delivering scalable regulatory-grade real-world data to accelerate evidence generation and product development.

News Market Reaction

-4.81%

14 alerts

-4.81% News Effect

-19.0% Trough in 28 hr 53 min

-$5M Valuation Impact

$99M Market Cap

0.2x Rel. Volume

On the day this news was published, ONMD declined 4.81%, reflecting a moderate negative market reaction. Argus tracked a trough of -19.0% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $99M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $0.7644 Vol: Volume 518,173 is below t...

low vol

$0.7644 Last Close

Volume Volume 518,173 is below the 20-day average of 2,559,164 (relative volume 0.2x). low

Technical Price $1.87 is trading above the 200-day MA $0.92, indicating a pre-news upswing.

Peers on Argus

ONMD was down 4.1% while peers showed mixed moves: BEAT up 3.27% (also flagged i...

1 Up 1 Down

ONMD was down 4.1% while peers showed mixed moves: BEAT up 3.27% (also flagged in momentum scanner at +60.12% earlier) and MGRX up 8.93% intraday but appearing in momentum data as -5.74%, with ZCMD, STRM, and HCTI modestly negative. This suggests stock-specific dynamics around ONMD’s RSNA update rather than a clear sector-wide move.

Common Catalyst Peer headlines feature AI and regulatory milestones (e.g., BEAT’s FDA clearance, HCTI’s AI acquisition), aligning with broader healthcare AI and data themes but not directly tied to ONMD’s RSNA presence.

Historical Context

5 past events · Latest: Nov 24 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 24	RSNA preview	Positive	-1.5%	Announced RSNA 2025 platform showcase built on Palantir Foundry and AIP.
Nov 20	Network expansion	Positive	-10.7%	Reported iRWD network growth in provider sites, patients, and exams.
Nov 17	Q3 results	Positive	-3.6%	Highlighted Q3 bookings growth, liability reduction, and higher inbound demand.
Nov 10	AI platform launch	Positive	+4.7%	Launched Palantir‑powered iRWD subscription products for live feeds and AI search.
Oct 20	New subscription	Positive	+23.3%	Signed multi‑year iRWD subscription with mlHealth360 to support AI models.

Pattern Detected

Recent ONMD news has generally been positive on operations and platform strategy, but share reactions have often been negative or muted, with several selloffs following seemingly strong updates and only occasional strong upside on select subscription wins or AI-platform milestones.

Recent Company History

Over the past few months, ONMD has focused on expanding its regulatory‑grade iRWD™ network and Palantir‑powered platform. Announcements included a multi‑year subscription with mlHealth360 on Oct 20, launch of Palantir‑based RWD subscriptions on Nov 10, Q3 results with an 815% bookings increase on Nov 17, and material network growth on Nov 20. A Nov 24 release previewed the RSNA 2025 platform showcase. Despite this operational momentum, price reactions often skewed negative, framing today’s RSNA follow‑up within a pattern of execution outpacing stock performance.

Market Pulse Summary

This announcement highlights strong engagement and perceived market validation for ONMD’s iRWD™ plat...

Analysis

This announcement highlights strong engagement and perceived market validation for ONMD’s iRWD™ platform at RSNA 2025, emphasizing demand for regulatory‑grade, AI‑ready datasets and faster cohort discovery. In context, recent filings showed Q3 2025 revenue of $177K, an operating loss of $2.24M, and management’s statement of substantial doubt about going‑concern status. Investors may watch how RSNA‑driven interest translates into recurring subscriptions and whether financial metrics and balance‑sheet strength improve from these levels.

Key Terms

real-world data (rwd), real-world evidence (rwe), observational studies, multimodal datasets, +4 more

8 terms

real-world data (rwd) medical

"provider of one of the world's largest regulatory-grade, AI-ready Real-World Data (RWD) network"

Real-world data are health and clinical information collected outside controlled clinical trials — from sources such as electronic health records, insurance claims, patient registries, wearable devices and pharmacy records. Investors care because this evidence shows how treatments or medical products actually perform in everyday use, informing market demand, regulatory decisions, reimbursement and commercial forecasts; think of it as street-level traffic data that complements lab tests and reduces uncertainty about real-market performance.

real-world evidence (rwe) medical

"supporting diverse patient representation in research, Real-World Evidence (RWE) programs, and observational"

Real-world evidence (RWE) is information about how drugs, devices or medical practices perform based on data collected outside controlled clinical trials, such as electronic health records, insurance claims, patient registries or wearable devices. For investors, RWE matters because it can reveal how a treatment works in everyday use, influence regulatory and reimbursement decisions, and reduce uncertainty about a product’s market potential—think of it as seeing how a product performs in customers’ homes versus a lab demonstration.

observational studies medical

"representation in research, Real-World Evidence (RWE) programs, and observational studies."

Observational studies are research projects that collect and analyze real-world data by watching what happens naturally, without assigning treatments or changing behavior — like noting how different drivers behave at an intersection rather than directing them. For investors they matter because they reveal how products, drugs or policies perform in everyday use, highlighting safety signals, adoption trends and market risks, but they can suggest associations rather than prove direct cause-and-effect.

multimodal datasets technical

"its ability to provide large-scale, high-fidelity multimodal datasets with speed, comprehensive"

Multimodal datasets are collections of information that combine different types of data — such as text, images, audio, and sensor readings — about the same subjects or events, like a photo with a caption and accompanying sound. Think of it as a mixed-media scrapbook that lets algorithms see more of the whole picture. Investors care because these richer datasets can enable more accurate AI-driven products, better customer insights and faster decision-making, which may translate into competitive advantages, higher growth potential and different risk profiles for companies.

post-market surveillance regulatory

"differentiator for research, post-market surveillance, and market access efforts."

Post-market surveillance is the ongoing monitoring of a product’s safety and performance after it has been approved and sold, especially for drugs and medical devices. Like watching cars after they leave the showroom to catch hidden defects, it matters to investors because problems discovered later can trigger recalls, regulatory fines, extra testing, or damaged reputation — all of which can reduce future sales and hurt a company’s financial outlook.

cohort discovery technical

"The platform's AI-enabled cohort discovery capabilities – reducing feasibility assessments"

Cohort discovery is the process of finding and defining a group of patients who meet specific medical or demographic criteria for a research study or clinical trial, typically by searching medical records, genetic data or other health information. For investors, effective cohort discovery speeds up patient recruitment, lowers trial costs and timelines, and improves the likelihood that a study will produce clear results—think of it as using a precise filter to find the right people in a crowd so a project can move forward efficiently.

regulatory-grade regulatory

"growing commercial traction... demand for high-quality, regulatory-grade RWD."

Regulatory-grade describes a product, test, dataset, system, or process that meets the strict standards set by government or industry regulators for safety, accuracy and reliability. For investors, a regulatory-grade label means lower approval risk and a clearer path to being accepted in official approvals, filings or government contracts — like a car that has passed crash tests and is ready to sell widely. It signals fewer technical hurdles, clearer timelines and a higher chance of converting development into sales or contracts.

ai-enabled technical

"The platform's AI-enabled cohort discovery capabilities – reducing feasibility"

AI-enabled describes a product, service, or process that uses artificial intelligence—software that learns from data and makes decisions or predictions—as a core feature rather than a minor add-on. For investors it matters because AI-enabled offerings can boost productivity, lower costs or unlock new revenue streams; like adding a smart autopilot to a routine task, they can change a company's growth potential and competitive edge while also bringing higher upfront investment needs and distinct regulatory or ethical risks.

AI-generated analysis. Not financial advice.

MINNEAPOLIS, Dec. 10, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), the leading curator and provider of one of the world's largest regulatory-grade, AI-ready Real-World Data (RWD) network, today announced significant engagement and growing commercial traction following a productive four days at the Radiological Society of North America (RSNA) Annual Meeting. Throughout the event, it was clear that hospitals, imaging centers, and life sciences innovators are eager to join the OneMedNet Network and utilize its updated iRWD™ platform, powered by Palantir Foundry.

RSNA 2025 provided clear market validation for OneMedNet across provider and life sciences ecosystems, affirming the Company's strategy amid increasing demand for high-quality, regulatory-grade RWD.

Healthcare providers expressed strong interest in partnering with OneMedNet to derive value from their clinical data assets while supporting diverse patient representation in research, Real-World Evidence (RWE) programs, and observational studies. Attendees highlighted OneMedNet's efficient, straightforward deployment model—a key advantage—along with opportunities for revenue streams through compliant data sharing.

“OneMedNet has consistently demonstrated an exceptional ability to rapidly source the clinical data we require and curate it with precision to our exact specifications. Their speed, data quality, and commitment to regulatory-grade standards are unmatched. This level of execution enables our teams to accelerate evidence generation and focus on delivering meaningful innovation. It’s why we continue to return to OneMedNet for our Real-World Data needs—they are a trusted strategic partner in our mission to advance impactful healthcare solutions.” says Shahzad Rauf, Chief Strategy Officer, Xylexa

Life sciences companies and AI developers demonstrated keen interest in the next-generation iRWD™ platform, supported by Palantir Foundry. Key features noted included its ability to provide large-scale, high-fidelity multimodal datasets with speed, comprehensive longitudinal coverage, and strong clinical accuracy. The platform's AI-enabled cohort discovery capabilities – reducing feasibility assessments from weeks to minutes– were identified as a valuable differentiator for research, post-market surveillance, and market access efforts.

"RSNA 2025 confirmed what we've been hearing from the market," said Aaron Green, President & CEO of OneMedNet. "Providers are seeking a reliable, low-effort way to participate in Healthcare innovation and research, while Health Sciences organizations need scalable, regulatory-grade multimodal datasets that are readily discoverable to accelerate product development and time to market for their solutions.. Our platform, built on Palantir Foundry, is addressing these needs effectively."

As OneMedNet continues to grow its provider network, enhance its multimodal data assets, and refine its platform capabilities, the Company remains focused on delivering regulatory-grade RWD at a global scale—supporting faster insights, robust evidence, and better outcomes for life sciences leaders, AI developers, and healthcare providers worldwide.

About OneMedNet Corporation

OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.

Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at www.onemednet.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements.  We base these forward-looking statements on our current expectations and projections about future events, which we derive from the information presently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial and operational performance, debt reductions, and their effect on achieving operational strategies of the company. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; and our ability to implement our Digital Asset treasury strategy and its effects on our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in our expectations.   Our ability to attract new customers and retain existing customers, market awareness and acceptance of enterprise AI solutions in general and our products in particular, the length and unpredictability of our sales cycles and the time and expense required for our sales efforts.

OneMedNet Contacts:

Michael Wong, VP Marketing

Email: michael.wong@onemednet.com

SOURCE: ONEMEDNET CORPORATION

FAQ

What did OneMedNet announce at RSNA on Dec 10, 2025 regarding its iRWD™ platform (ONMD)?

OneMedNet said its updated iRWD™ platform, built on Palantir Foundry, drew strong interest for large-scale multimodal data and faster AI-enabled cohort discovery.

How does OneMedNet say iRWD™ improves feasibility timelines for research (ONMD)?

The company reported AI-enabled cohort discovery on iRWD™ can reduce feasibility assessments from weeks to minutes.

Which groups expressed interest in joining the OneMedNet network at RSNA 2025 (ONMD)?

Hospitals, imaging centers, life sciences companies, and AI developers expressed interest in joining OneMedNet's provider network.

What deployment and data advantages did RSNA attendees highlight for OneMedNet (ONMD)?

Attendees highlighted efficient, low-effort deployment, regulatory-grade data quality, comprehensive longitudinal coverage, and revenue-sharing opportunities through compliant data sharing.

Will OneMedNet expand its provider network after RSNA 2025 (ONMD)?

The company said it will continue to grow its provider network and enhance multimodal data assets to deliver regulatory-grade real-world data at scale.

How does OneMedNet position its data for life sciences and AI developers (ONMD)?

OneMedNet positions its datasets as scalable, regulatory-grade, multimodal, and readily discoverable to accelerate evidence generation and time to market.